Biomerica's $300 Medicare Reimbursement Lifts a Personalized IBS Test

For the roughly 35 million Americans with irritable bowel syndrome, the path to relief is often a frustrating cycle of trial and error. The standard of care, a process of elimination diets and symptom tracking, can take months or years. Biomerica, a publicly traded diagnostic company founded in 1971, is betting a simple blood test can offer a faster, more precise answer. Its inFoods IBS platform aims to identify patient-specific food triggers from a single sample, a proposition that has recently secured a critical foothold: 100% of initial Medicare claims for the test have been paid at the full $300 CMS rate.

This reimbursement win, alongside a new $1.75 million contract development agreement, represents a pivotal moment for a company navigating a challenging financial landscape. Quarterly sales rose 17% year-over-year as of September 2026, yet annual revenue for fiscal 2026 was approximately $4.50 million, down from $5.30 million the prior year [Orange County Business Journal, September 2026] [16]. The recent $2.23 million private placement, led by B. Riley Principal Capital, is intended to support operations while the board, advised by B. Riley Securities, evaluates strategic alternatives [investors.biomerica.com, August 2026].

The Clinical Wedge: From Diagnosis to Intervention

Biomerica's portfolio includes traditional in-vitro diagnostics like its hp+detect H. pylori test, which recently landed a first commercial order from one of Europe's largest clinical laboratory chains. But the company's strategic focus is increasingly on platforms that combine testing with an actionable clinical intervention. The inFoods IBS test is the flagship of this approach.

The test analyzes a blood sample for IgG antibody reactions to a panel of common foods, generating a report that identifies which foods may be linked to a patient's IBS symptoms. The goal is not just to diagnose, but to directly inform a personalized dietary management plan. This positions it differently from a pure diagnostic; it's a tool intended to guide a therapeutic conversation between patient and physician. Early commercial traction includes an exclusive Canadian distribution partnership with Phoenix Airmid Biomedical and testing services through CanAlt Health Labs.

Building a Commercial Bridge

Translating clinical utility into commercial scale requires navigating complex pathways. Biomerica's recent moves suggest a multi-pronged strategy to build that bridge.

• Reimbursement First. Securing consistent Medicare payment is a foundational step for any novel diagnostic seeking broad physician adoption. The reported 100% payment rate at the $300 CMS fee is a significant early validation of the test's perceived value in the healthcare system.
• Channel Partnerships. A marketing services agreement with medical distributor Henry Schein aims to put the inFoods test in front of U.S. physicians, leveraging an established sales network [22, 23, 24].
• Diversification via CDMO. Alongside its own products, Biomerica is formalizing a Contract Development and Manufacturing Organization (CDMO) service. The $1.75 million master-services agreement to develop proprietary IVD assays for a confidential life sciences partner demonstrates this unit's potential to generate milestone-based revenue and utilize existing manufacturing expertise.

The Board's Strategic Hand

The company's leadership and governance have seen notable reinforcements, particularly on the commercial and strategic fronts. CEO Zack Irani has led the company since 1997 [Crunchbase, retrieved 2026]. In 2025, the board appointed Scott Madel, a veteran with experience at Quest Diagnostics and Roche, as Chief Commercial Officer to spearhead commercial strategy [9, 10, 12].

The board itself has added significant diagnostics industry weight. Recent appointments include Jack Kenny, a diagnostics industry leader, as Chairman, and Gary Huff, the former CEO of LabCorp Diagnostics [BioSpace, retrieved 2026] [investors.biomerica.com, retrieved 2026]. This collective experience in scaling lab networks and navigating payer landscapes appears directly aligned with the challenges ahead for inFoods IBS.

Fiscal 2025 Revenue | 5.3 | M USD
Fiscal 2026 Revenue | 4.5 | M USD
Q1 2026 Revenue | 1.38 | M USD
Q4 2026 Revenue | 0.88 | M USD

Navigating the Counterfactuals

The path forward is not without clear headwinds. Revenue has contracted, and the company's gross margin remained near 8% for fiscal 2026, reflecting the cost-intensive nature of its manufacturing and development work. While the net loss improved by about 24% to $3.8 million, this was aided by a one-time $1.1 million Employee Retention Credit. The core commercial motion for inFoods IBS,convincing physicians to order a novel, personalized test,is still in its early days, with expansion cited to "200+ physicians" [7].

The company's answer to these challenges rests on the strategic review and the use points it is building. The CDMO business offers a path to higher-margin service revenue. The Medicare reimbursement code provides a predictable economic model for the IBS test. And the board's engagement with B. Riley Securities suggests a proactive search for partnerships or transactions that could provide a more substantial capital base or accelerate market access [investors.biomerica.com, August 2026].

The Next Twelve Months

The coming year will be decisive for Biomerica's bet. Key milestones to watch include the scale-up of physician adoption for inFoods IBS beyond the initial 200, the signing of additional CDMO clients, and the outcome of the strategic review. Success will be measured not just in revenue growth, but in the margin profile of that growth and the demonstrated repeatability of the inFoods commercial model.

For patients with irritable bowel syndrome, the standard of care today is often a protracted and isolating process of dietary exclusion, guided by food diaries and guesswork. It is a condition managed through persistent patient diligence rather than cured by a definitive test. Biomerica's proposition is to replace that ambiguity with a data-driven starting point. The company's future now hinges on proving that this clinical insight can be delivered not just accurately, but also profitably and at scale, turning a personalized blood test into a new standard in gastrointestinal care.

Sources

1. [Biomerica, August 2026] Biomerica Announces $2.23 Million Financing | https://investors.biomerica.com/news/news-details/2026/Biomerica-Announces-2-23-Million-Financing/default.aspx
2. [Orange County Business Journal, September 2026] Biomerica Raises $2.23 Million as Quarterly Sales Rise 17% | https://www.ocbj.com/healthcare/biomerica-raises-2-23m-in-private-placement/
3. [Marketscreener, September 2026] Biomerica Reports Fiscal 2026 Year-End Financial Results | https://investors.biomerica.com/news/news-details/2026/Biomerica-Reports-Fiscal-2026-Year-End-Financial-Results/default.aspx
4. [Biomerica] Home - Biomerica | https://biomerica.com/
5. [LinkedIn, retrieved 2026] Biomerica, Inc. | LinkedIn | https://www.linkedin.com/company/biomerica
6. [Crunchbase, retrieved 2026] Biomerica - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/biomerica
7. [Perplexity Sonar Pro Brief, August 2026] Biomerica Company Brief
8. [BioSpace, retrieved 2026] Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica | https://www.biospace.com/diagnostics-industry-leader-jack-kenny-appointed-as-chairman-of-the-board-at-biomerica
9. [investors.biomerica.com, retrieved 2026] Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors | https://investors.biomerica.com/news/news-details/2025/Gary-Huff-Former-CEO-of-LabCorp-Diagnostics-Appointed-to-Biomerica-Board-of-Directors/default.aspx
10. [Crunchbase, retrieved 2026] Scott Madel appointed Chief Commercial Officer | https://www.crunchbase.com/person/scott-madel
11. [investors.biomerica.com] Biomerica, Inc. - Investor Relations | https://investors.biomerica.com/overview/default.aspx
12. [9, 10, 12] Scott Madel appointment references
13. [22, 23, 24] Henry Schein marketing agreement references
14. [14] Q1 2026 revenue reference
15. [15] Q4 2026 revenue reference
16. [16] Fiscal 2026 financial results reference